To explore the hypothesis that pretreatment of GBM with BTZ might sensitize patient tumours to lysis by autologous NK cells, we first investigated the efficacy of BTZ against P3, 2012-018, and BG7 cells, and determined its half maximal inhibitory concentration (IC50) after treatment for 24 or 48 h. The gene discussed is CASC3; the disease is neoplasm.